Drug prescription for attention deficit hyperactivity disorder drugs in pediatric outpatients: A retrospective survey of Japanese administrative data (2012–2018)

Daisuke Kikuchi; Taku Obara; Misaki Tokunaga; Makoto Shiozawa; Ai Takahashi; Misato Ito; Hiroaki Hino; Ryosuke Miura; Sachiko Hayakawa; Yoshiteru Watanabe

doi:10.1016/j.ajp.2020.102512

Drug prescription for attention deficit hyperactivity disorder drugs in pediatric outpatients: A retrospective survey of Japanese administrative data (2012–2018)

Daisuke Kikuchi, Taku Obara, Misaki Tokunaga, Makoto Shiozawa, Ai Takahashi, Misato Ito, Hiroaki Hino, Ryosuke Miura, Sachiko Hayakawa, Yoshiteru Watanabe

Tohoku Medical Megabank Organization (ToMMo)

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

We aimed to clarify the prescription trend of ADHD drugs in Japanese pediatric outpatients. From January 2012 to December 2018, we evaluated the trends of prescribing methylphenidate-osmotic-controlled release oral delivery system (OROS), atomoxetine, and guanfacine as monotherapy. In boys, methylphenidate-OROS and atomoxetine prescriptions decreased from 46.5 % to 37.2 % and 18.6 % to 15.6 %, respectively. Prescriptions of guanfacine increased from 0.0 % to 12.3 %. In girls, the methylphenidate-OROS prescriptions was not significantly different (37.0 % to 26.4 %); however, atomoxetine decreased from 23.1 % to 16.3 %, and guanfacine increased from 0.0 % to 12.8 %. Methylphenidate-OROS and atomoxetine prescriptions changed to guanfacine between 2012 and 2018.

Original language	English
Article number	102512
Journal	Asian Journal of Psychiatry
Volume	57
DOIs	https://doi.org/10.1016/j.ajp.2020.102512
Publication status	Published - 2021 Mar

Keywords

Attention deficit hyperactivity disorder
Guanfacine
Pediatric
Prescription
Prevalence

ASJC Scopus subject areas

Psychology(all)
Psychiatry and Mental health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ajp.2020.102512

Cite this

Kikuchi, D., Obara, T., Tokunaga, M., Shiozawa, M., Takahashi, A., Ito, M., Hino, H., Miura, R., Hayakawa, S., & Watanabe, Y. (2021). Drug prescription for attention deficit hyperactivity disorder drugs in pediatric outpatients: A retrospective survey of Japanese administrative data (2012–2018). Asian Journal of Psychiatry, 57, [102512]. https://doi.org/10.1016/j.ajp.2020.102512

Kikuchi, D, Obara, T, Tokunaga, M, Shiozawa, M, Takahashi, A, Ito, M, Hino, H, Miura, R, Hayakawa, S & Watanabe, Y 2021, 'Drug prescription for attention deficit hyperactivity disorder drugs in pediatric outpatients: A retrospective survey of Japanese administrative data (2012–2018)', Asian Journal of Psychiatry, vol. 57, 102512. https://doi.org/10.1016/j.ajp.2020.102512

@article{fcb5eeec0865486f96dea24f83a3307e,

title = "Drug prescription for attention deficit hyperactivity disorder drugs in pediatric outpatients: A retrospective survey of Japanese administrative data (2012–2018)",

abstract = "We aimed to clarify the prescription trend of ADHD drugs in Japanese pediatric outpatients. From January 2012 to December 2018, we evaluated the trends of prescribing methylphenidate-osmotic-controlled release oral delivery system (OROS), atomoxetine, and guanfacine as monotherapy. In boys, methylphenidate-OROS and atomoxetine prescriptions decreased from 46.5 % to 37.2 % and 18.6 % to 15.6 %, respectively. Prescriptions of guanfacine increased from 0.0 % to 12.3 %. In girls, the methylphenidate-OROS prescriptions was not significantly different (37.0 % to 26.4 %); however, atomoxetine decreased from 23.1 % to 16.3 %, and guanfacine increased from 0.0 % to 12.8 %. Methylphenidate-OROS and atomoxetine prescriptions changed to guanfacine between 2012 and 2018.",

keywords = "Attention deficit hyperactivity disorder, Guanfacine, Pediatric, Prescription, Prevalence",

author = "Daisuke Kikuchi and Taku Obara and Misaki Tokunaga and Makoto Shiozawa and Ai Takahashi and Misato Ito and Hiroaki Hino and Ryosuke Miura and Sachiko Hayakawa and Yoshiteru Watanabe",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier B.V.",

year = "2021",

month = mar,

doi = "10.1016/j.ajp.2020.102512",

language = "English",

volume = "57",

journal = "Asian Journal of Psychiatry",

issn = "1876-2018",

publisher = "Elsevier",

}

TY - JOUR

T1 - Drug prescription for attention deficit hyperactivity disorder drugs in pediatric outpatients

T2 - A retrospective survey of Japanese administrative data (2012–2018)

AU - Kikuchi, Daisuke

AU - Obara, Taku

AU - Tokunaga, Misaki

AU - Shiozawa, Makoto

AU - Takahashi, Ai

AU - Ito, Misato

AU - Hino, Hiroaki

AU - Miura, Ryosuke

AU - Hayakawa, Sachiko

AU - Watanabe, Yoshiteru

PY - 2021/3

Y1 - 2021/3

N2 - We aimed to clarify the prescription trend of ADHD drugs in Japanese pediatric outpatients. From January 2012 to December 2018, we evaluated the trends of prescribing methylphenidate-osmotic-controlled release oral delivery system (OROS), atomoxetine, and guanfacine as monotherapy. In boys, methylphenidate-OROS and atomoxetine prescriptions decreased from 46.5 % to 37.2 % and 18.6 % to 15.6 %, respectively. Prescriptions of guanfacine increased from 0.0 % to 12.3 %. In girls, the methylphenidate-OROS prescriptions was not significantly different (37.0 % to 26.4 %); however, atomoxetine decreased from 23.1 % to 16.3 %, and guanfacine increased from 0.0 % to 12.8 %. Methylphenidate-OROS and atomoxetine prescriptions changed to guanfacine between 2012 and 2018.

AB - We aimed to clarify the prescription trend of ADHD drugs in Japanese pediatric outpatients. From January 2012 to December 2018, we evaluated the trends of prescribing methylphenidate-osmotic-controlled release oral delivery system (OROS), atomoxetine, and guanfacine as monotherapy. In boys, methylphenidate-OROS and atomoxetine prescriptions decreased from 46.5 % to 37.2 % and 18.6 % to 15.6 %, respectively. Prescriptions of guanfacine increased from 0.0 % to 12.3 %. In girls, the methylphenidate-OROS prescriptions was not significantly different (37.0 % to 26.4 %); however, atomoxetine decreased from 23.1 % to 16.3 %, and guanfacine increased from 0.0 % to 12.8 %. Methylphenidate-OROS and atomoxetine prescriptions changed to guanfacine between 2012 and 2018.

KW - Attention deficit hyperactivity disorder

KW - Guanfacine

KW - Pediatric

KW - Prescription

KW - Prevalence

UR - http://www.scopus.com/inward/record.url?scp=85099706833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85099706833&partnerID=8YFLogxK

U2 - 10.1016/j.ajp.2020.102512

DO - 10.1016/j.ajp.2020.102512

M3 - Article

C2 - 33486336

AN - SCOPUS:85099706833

SN - 1876-2018

VL - 57

JO - Asian Journal of Psychiatry

JF - Asian Journal of Psychiatry

M1 - 102512

ER -

Drug prescription for attention deficit hyperactivity disorder drugs in pediatric outpatients: A retrospective survey of Japanese administrative data (2012–2018)

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this